Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Eagle Pharmaceuticals	SIGA Technologies	Relmada Therapeutics	Crinetics Pharmaceuticals	Mirum Pharmaceuticals
Symbol	NASDAQ:EGRX	NASDAQ:SIGA	NASDAQ:RLMD	NASDAQ:CRNX	NASDAQ:MIRM
Price Information
Current Price	$41.65	$7.33	$36.34	$16.96	$18.67
52 Week Range	N/A	N/A	Buy	Buy	Buy
MarketRank™
Overall Score	1.0	0.3	1.1	1.8	1.8
Analysis Score	0.0	0.0	3.3	3.4	3.6
Community Score	2.9	0.0	1.4	2.2	2.7
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	1.7	0.0	0.8	3.3	2.5
Earnings & Valuation Score	0.6	1.3	0.0	0.0	0.0
Analyst Ratings
Consensus Recommendation	N/A	N/A	Buy	Buy	Buy
Consensus Price Target	N/A	N/A	$57.50	$36.75	$40.17
% Upside from Price Target	N/A	N/A	58.23% upside	116.69% upside	115.14% upside
Trade Information
Market Cap	$546.41 million	$557.56 million	$608.59 million	$637.58 million	$568.35 million
Beta	0.74	0.53	0.53	1.24	2.44
Average Volume	117,341	265,013	69,727	136,517	127,498
Sales & Book Value
Annual Revenue	$195.89 million	$26.74 million	N/A	$1.19 million	N/A
Price / Sales	2.79	20.85	N/A	535.78	N/A
Cashflow	$1.52 per share	N/A	N/A	N/A	N/A
Price / Cash	27.49	N/A	N/A	N/A	N/A
Book Value	$13.11 per share	$1.21 per share	$7.88 per share	$4.84 per share	$5.67 per share
Price / Book	3.18	6.06	N/A	3.50	N/A
Profitability
Net Income	$14.31 million	$-7,240,000.00	N/A	$-50,420,000.00	$-52,550,000.00
EPS	$1.38	N/A	($2.16)	($2.09)	($4.58)
Trailing P/E Ratio	119.00	18.33	N/A	N/A	N/A
Forward P/E Ratio	138.83	∞	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	2.65%	34.62%	N/A	N/A	N/A
Return on Equity (ROE)	8.50%	37.31%	-32.03%	-43.35%	-61.90%
Return on Assets (ROA)	5.44%	25.33%	-31.41%	-39.73%	-54.46%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	0.16%	N/A	N/A	N/A	N/A
Current Ratio	3.60%	8.04%	37.02%	21.98%	7.35%
Quick Ratio	3.45%	7.38%	37.02%	21.98%	7.35%
Ownership Information
Institutional Ownership Percentage	95.12%	29.28%	64.31%	92.15%	72.90%
Insider Ownership Percentage	21.10%	3.91%	9.30%	7.10%	45.50%
Miscellaneous
Employees	106	42	14	93	68
Shares Outstanding	13.12 million	76.07 million	16.75 million	37.59 million	30.44 million
Next Earnings Date	5/10/2021 (Confirmed)	8/5/2021 (Estimated)	N/A	8/6/2021 (Estimated)	8/5/2021 (Estimated)
Optionable	Optionable	Optionable	Optionable	Not Optionable	Not Optionable

Source	Headline
	Mirum Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update businesswire.com - May 7 at 2:16 AM
	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Lags Revenue Estimates nasdaq.com - May 6 at 9:15 PM
	Mirum Pharmaceuticals Inc to Host Earnings Call finance.yahoo.com - May 6 at 4:15 PM
	Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Average Recommendation of "Buy" by Brokerages americanbankingnews.com - May 2 at 2:20 AM
	Mirum Pharmaceuticals Inc (MIRM) investing.com - April 30 at 2:22 PM
	Mirum Pharmaceuticals (MIRM) Set to Announce Quarterly Earnings on Thursday americanbankingnews.com - April 30 at 9:58 AM
	Mirum Pharmaceuticals to Report First Quarter 2021 Financial Results and Host Conference Call on May 6, 2021 finance.yahoo.com - April 29 at 7:47 PM
	Mirum Pharmaceuticals and CANbridge Pharmaceuticals Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat in Greater China us.acrofan.com - April 29 at 9:40 AM
	Mirum Pharmaceuticals and CANbridge Pharmaceuticals Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat in Greater China for Rare Liver Diseases finance.yahoo.com - April 29 at 9:40 AM
	Mirum Pharmaceuticals (NASDAQ:MIRM) Is In A Good Position To Deliver On Growth Plans nasdaq.com - April 27 at 9:24 AM
	Mirum Pharmaceuticals Receives Notice of Allowance for Methods of Use Patent for Maralixibat in Alagille Syndrome finance.yahoo.com - April 26 at 1:01 PM
	Mirum Pharmaceuticals (NASDAQ:MIRM) Shares Gap Down to $18.63 americanbankingnews.com - April 22 at 12:52 PM
	Mirum Pharmaceuticals (NASDAQ:MIRM) Shares Gap Up to $17.86 americanbankingnews.com - April 21 at 12:56 PM
	Mirum Pharmaceuticals (NASDAQ:MIRM) Shares Gap Up to $18.00 americanbankingnews.com - April 14 at 12:42 PM
	Mirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and License Agreement for Vivet’s Gene Therapy Programs Targeting Progressive Familial ... businesswire.com - April 12 at 11:30 PM
	Mirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and License Agreement for Vivet’s Gene Therapy Programs Targeting Progressive Familial Intrahepatic Cholestasis finance.yahoo.com - April 12 at 1:29 PM
	Mirum Pharmaceuticals Announces FDA Acceptance of New Drug Application and Priority Review for Maralixibat in Alagille Syndrome finance.yahoo.com - March 29 at 12:50 PM
	Mirum Pharmaceuticals Inc reuters.com - March 17 at 3:23 PM
	Have Insiders Been Buying Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares? finance.yahoo.com - March 13 at 6:13 PM
	Mirum Pharmaceuticals (MIRM) Receives a Buy from Leerink Partners smarteranalyst.com - March 11 at 1:12 PM
	Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Results and Provides Business Updates finance.yahoo.com - March 9 at 8:47 PM
	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Lags Revenue Estimates finance.yahoo.com - March 9 at 8:47 PM
	Why Earnings Season Could Be Great for Mirum Pharmaceuticals (MIRM) finance.yahoo.com - March 9 at 10:46 AM
	Mirum Pharmaceuticals Announces Completion of Rolling NDA Submission for Maralixibat in Alagille Syndrome finance.yahoo.com - February 1 at 1:06 PM
	Mirum Pharmaceuticals Honors Alagille SyndromeAwareness Day with Launch of Disease Awareness Campaign marketwatch.com - January 24 at 5:38 PM

Date	Company	Brokerage	Action
4/20/2020	Eagle Pharmaceuticals	Cantor Fitzgerald	Reiterated Rating
3/25/2020	Eagle Pharmaceuticals	Royal Bank of Canada	Reiterated Rating
4/24/2019	Eagle Pharmaceuticals	Mizuho	Reiterated Rating
10/31/2018	Eagle Pharmaceuticals	Piper Jaffray Companies	Downgrade
3/17/2021	Relmada Therapeutics	Oppenheimer	Reiterated Rating
10/28/2020	Relmada Therapeutics	The Goldman Sachs Group	Downgrade
5/4/2020	Relmada Therapeutics	SunTrust Banks	Initiated Coverage
1/27/2020	Relmada Therapeutics	Jefferies Financial Group	Initiated Coverage
1/10/2020	Relmada Therapeutics	SVB Leerink	Reiterated Rating
12/16/2019	Relmada Therapeutics	Guggenheim	Initiated Coverage
5/3/2021	Crinetics Pharmaceuticals	Jonestrading	Initiated Coverage
11/9/2020	Crinetics Pharmaceuticals	HC Wainwright	Reiterated Rating
10/14/2020	Crinetics Pharmaceuticals	JPMorgan Chase & Co.	Initiated Coverage
12/23/2019	Crinetics Pharmaceuticals	Roth Capital	Initiated Coverage
4/1/2021	Mirum Pharmaceuticals	Robert W. Baird	Reiterated Rating
11/13/2020	Mirum Pharmaceuticals	Raymond James	Boost Price Target
9/1/2020	Mirum Pharmaceuticals	Citigroup	Boost Price Target
7/30/2020	Mirum Pharmaceuticals	Piper Sandler	Initiated Coverage
8/12/2019	Mirum Pharmaceuticals	Evercore ISI	Initiated Coverage

(Data available from 5/7/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources